Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis

NCT03692065 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT03692065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03692065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 3
Overall status
Completed
Start date
October 11, 2018
Completion date
October 20, 2024
Enrollment
1,766 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

cancer-associated thrombosis